- Home
- NRGV vs PLX Comparison
NRGV vs PLX Comparison
Compare NRGV & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- PLX
- Stock Information
- Founded
- NRGV 2017
- PLX 1993
- Country
- NRGV United States
- PLX United States
- Employees
- NRGV N/A
- PLX N/A
- Industry
- NRGV Industrial Machinery/Components
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRGV Miscellaneous
- PLX Health Care
- Exchange
- NRGV Nasdaq
- PLX Nasdaq
- Market Cap
- NRGV 133.4M
- PLX 127.4M
- IPO Year
- NRGV N/A
- PLX 1998
- Fundamental
- Price
- NRGV $1.48
- PLX $1.48
- Analyst Decision
- NRGV Buy
- PLX Strong Buy
- Analyst Count
- NRGV 3
- PLX 1
- Target Price
- NRGV $1.58
- PLX $15.00
- AVG Volume (30 Days)
- NRGV 2.7M
- PLX 543.0K
- Earning Date
- NRGV 08-07-2025
- PLX 08-14-2025
- Dividend Yield
- NRGV N/A
- PLX N/A
- EPS Growth
- NRGV N/A
- PLX N/A
- EPS
- NRGV N/A
- PLX 0.08
- Revenue
- NRGV $51,716,000.00
- PLX $61,948,000.00
- Revenue This Year
- NRGV $356.46
- PLX $10.00
- Revenue Next Year
- NRGV $34.31
- PLX $83.13
- P/E Ratio
- NRGV N/A
- PLX $19.11
- Revenue Growth
- NRGV N/A
- PLX 62.79
- 52 Week Low
- NRGV $0.60
- PLX $0.89
- 52 Week High
- NRGV $2.70
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- NRGV 66.61
- PLX 46.48
- Support Level
- NRGV $1.34
- PLX $1.41
- Resistance Level
- NRGV $1.60
- PLX $1.68
- Average True Range (ATR)
- NRGV 0.17
- PLX 0.08
- MACD
- NRGV 0.03
- PLX 0.01
- Stochastic Oscillator
- NRGV 68.66
- PLX 25.93
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.